The Saudi Food and Drug Authority (SFDA) has approved the registration of Jascayd (nerandomilast) for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).
From the publisher's summary
Segal shows this headline and a short summary for reference. The full report belongs to Saudi Gazette and is available on its website.





